Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Quantum BioPharma Ltd C.QNTM

Alternate Symbol(s):  QNTM

Quantum BioPharma Ltd. is a Canada-based biopharmaceutical company. The Company is engaged in building a portfolio of assets and biotech solutions for the treatment of challenging neurodegenerative and metabolic disorders and alcohol misuse disorders with drug candidates in different stages of development. Through its wholly owned subsidiary, Lucid Psycheceuticals Inc. (Lucid), it is focused on the research and development of its lead compound, Lucid-MS, which is a patented new chemical entity to prevent and reverse myelin degradation, the underlying mechanism of multiple sclerosis. Its unbuzzd beverage is a proprietary formulation of vitamins and minerals to help with liver and brain function for the purposes of relieving the effects of alcohol consumption and restoring a normal lifestyle. It maintains a portfolio of strategic investments through its wholly owned subsidiary, FSD Strategic Investments Inc., which represents loans secured by residential or commercial property.


CSE:QNTM - Post by User

Post by KandiBirdBoyon Apr 27, 2021 7:04pm
33 Views
Post# 33079549

FSD Pharma Management Needs to go !! VOTE GOLD

FSD Pharma Management Needs to go !! VOTE GOLD

Misleading Statements by FSD Management

 
Management of FSD claim that the Concerned Shareholders are single-mindedly seeking to pursue the acquisition of a particular early-stage company in the psychedelics sector (the “Target”). This is simply not true. The proposed acquisition of the Target was previously rejected by Dr. Bokhari and the Concerned Shareholders now have no interest in pursuing a transaction with the Target. The truth, however, is that it was the manner in which Dr. Bokhari responded to this opportunity that elevated existing concerns of the Concerned Shareholders and ultimately led them to take action. The continued assertions that the Concerned Shareholders are acting to pursue this specific transaction (or any other transaction with the Target) are simply convenient misdirections of Shareholder attention away from the very real concerns with the actions of Dr. Bokhari and the Collaborating Directors that risk irreparable harm to FSD.
 
Management of FSD claim the Concerned Shareholders have undisclosed interests in the Target. This also is simply not true. Mr. Durkacz and his family were the only members of the Concerned Shareholders who had an interest in the Target, being an indirect minority ownership interest of approximately 6%, and he disclosed this interest orally to management on November 16, 2020 and then to the entire Board on November 17, 2020. This disclosure is confirmed in the written minutes of the Board. While this issue is irrelevant at this time, as there is no intention of having FSD enter into a transaction with the Target, the willful misrepresentation of verifiable facts is used by Dr. Bokhari and the Collaborating Directors as a misdirection of Shareholder attention.

<< Previous
Bullboard Posts
Next >>